Combined flurbiprofen and cyclosporin-A does not attenuate bone loss and exaggerates renal impairment.
Cyclosporine (CsA) is a potent immunosuppressant that has revolutionized the success of organ transplantation. Flurbiprofen (FB), a propionic acid derivative NSAID, has been demonstrated in vivo to reduce osteoclast numbers in normal rats. The aim of this experiment was to determine whether addition of FB to CsA-treated rats could prevent the bone changes associated with CsA therapy. Forty-eight 10-12-week-old male Sprague-Dawley rats were randomized to receive, daily for 28 days: (1) CsA vehicle p.o. plus FB vehicle sc; (2) CsA (15 mg/kg) p.o. plus FB vehicle sc, (3) CsA vehicle p.o. plus FB (1.5 mg/kg) sc; and (4) CsA (15 mg/kg) p.o. plus FB (1.5 mg/kg) sc. Rats were weighed and venous blood sampled at baseline, 14 days, and 28 days for determination of glucose, Ca+2, BUN, creatinine, PTH, osteocalcin, and 1,25(OH)2 vitamin D. Tibiae were removed following killing, after double labeling for histomorphometry. Body mass was significantly lower than control in all rats receiving CsA on days 14 and 28 while blood glucose was only elevated in the CsA alone group. Day 28 BUN and creatinine were significantly elevated in the CsA group and the combination of CsA and FB revealed an exacerbation of this trend. Vitamin D and osteocalcin were consistently increased in the CsA and CsA/FB groups. Bone histomorphometry showed evidence of trabecular osteopenia in CsA and CsA/FB groups. CsA alone resulted in elevated bone turnover. FB was unable to prevent the trabecular bone loss induced by CsA therapy. This experiment indicates no role for FB as a therapeutic option in CsA-induced bone disease at the given doses and duration of treatment by virtue of its lack of bone sparing ability and adverse renal effects when the two drugs are administered concurrently.
Sass
D A
DA
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, USA.
Rucinski
B
B
Bryer
H P
HP
Mann
G N
GN
Yuan
Z
Z
Ma
Y
Y
Jee
W S
WS
Epstein
S
S
D000284:Administration, Oral; D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000633:toxicity*; D001786:Blood Glucose / Q000032:analysis; D001806:Blood Urea Nitrogen; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood; D002452:Cell Count; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000633:toxicity*; D005480:Flurbiprofen / Q000008:administration & dosage / Q000633:toxicity*; D015592:Immunoradiometric Assay; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000633:toxicity*; D007279:Injections, Subcutaneous; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007677:Kidney Function Tests; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D010024:Osteoporosis / Q000139:chemically induced*; D010281:Parathyroid Hormone / Q000097:blood; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000166:cytology / Q000187:drug effects / Q000473:pathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D007166:Immunosuppressive Agents; D010281:Parathyroid Hormone; D015675:Osteocalcin; D005480:Flurbiprofen; D016572:Cyclosporine; D003404:Creatinine; D002117:Calcitriol; D002118:Calcium